In TRAPS, an autoinflammatory disorder caused by mutations in TNF receptor type 1, anakinra has been effective in treating refractory cases [127], suggesting an important role for IL-1 in the inflammatory process created by a defect in a TNF-mediated disease. This evidence concerns the gene IL1A and TNF receptor 1-associated periodic fever syndrome.